Immune Tolerance Network
The Immune Tolerance Network (ITN) is a federally funded research consortium sponsored by NIAID/NIH that develops and conducts mechanistic clinical trials across allergy, autoimmune disease, transplantation, and type 1 diabetes to advance immune tolerance therapies.
- Company typePrivate
- Founded-
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Immune Tolerance Network does
The Immune Tolerance Network (ITN) is a federally sponsored clinical research consortium that develops, funds, and conducts mechanistic clinical trials aimed at re-establishing immune tolerance across four therapeutic areas: allergy and asthma, autoimmune disease, transplantation, and type 1 diabetes. ITN's core technical assets include the TrialShare data platform, which provides public access to raw clinical trial data, analyses, and banked specimens (including plasma from 582+ LEAP trial participants), and a suite of standardized immune monitoring assays measuring islet-specific T cell responses, immune phenotypes, and tolerance biomarkers. The network's trial portfolio encompasses ongoing studies such as EVEREST (liver transplant tolerance), REBOOT (Primary Membranous Nephropathy), BEAT-MS (multiple sclerosis), VIBRANT (lupus nephritis), DESIGNATE (siplizumab in T1D), and EXTEND (tocilizumab in T1D), conducted across leading academic medical centers including UCSF, Benaroya Research Institute, Northwestern, Yale, and Indiana University.
ITN operates as a non-profit research consortium under the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with offices at the Benaroya Research Institute in Seattle and at UCSF in San Francisco. The organization does not charge patients for trial participation and generates no commercial product revenue; its operating model relies on federal appropriations channeled through NIAID, supplemented by collaborative partnerships with patient advocacy organizations (JDRF, Diabetes UK) and trial consortia (TrialNet). The organization is led by Network Director Mark Anderson MD PhD (UCSF), Deputy Director for Transplantation Chris Larsen, Senior Advisor Gerald Nepom, Chief Administrative Officer Mary Roy, Executive Director of Strategic Review Philip Bernstein, and Clinical Trial Physician for Allergy Michelle Huffaker. Notable scientific outcomes include ITN's foundational AbATE trial work that supported the 2026 FDA approval of teplizumab (Tzield) as the first disease-modifying therapy for stage 3 type 1 diabetes, and the LEAP/LEAP-On studies that established early peanut consumption as a strategy to reduce peanut allergy risk in infants.
Immune Tolerance Network firmographics
Firmographics- Name
- Immune Tolerance Network
- Legal name
- Immune Tolerance Network
- Website
- https://immunetolerance.org
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- The Immune Tolerance Network (ITN) is a federally funded research consortium sponsored by NIAID/NIH that develops and conducts mechanistic clinical trials across allergy, autoimmune disease, transplantation, and type 1 diabetes to advance immune tolerance therapies.
- Ownership category
- akta.pro rank
Immune Tolerance Network industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
- akta.pro primary industry
- Autoimmune & Allergy Diagnostics (HLAAALAK)
Keywords
Where Immune Tolerance Network is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Immune Tolerance Network business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Government Research Funding: ITN is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, providing primary funding for clinical trials and research operations
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Immune Tolerance Network product offering
Product offeringCore offering
ITN is a research consortium that develops, funds, and conducts mechanistic clinical trials designed to re-establish immune tolerance in four therapeutic areas: allergy & asthma, autoimmune disease, transplantation, and type 1 diabetes. It operates TrialShare, a web-based data sharing platform providing researchers with access to raw clinical trial data, analysis tools, and banked clinical specimens from over 15 years of trials.
Product overview
The Immune Tolerance Network (ITN) is a research consortium that develops, funds, and conducts clinical trials in immune tolerance. The organization operates TrialShare as its primary data platform providing access to raw clinical trial data, analyses, and specimens. ITN's clinical trial portfolio spans four therapeutic areas: Allergy & Asthma, Autoimmune Disease, Transplantation, and Type 1 Diabetes. The network conducts mechanistic-based clinical studies designed to test specific immune tolerance pathways and partners with industry and other consortia to accelerate development of tolerance-inducing therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- TrialShare A web-based data sharing platform that provides researchers with access to raw data, analysis tools, and clinical specimens from ITN's clinical trials in immune tolerance across four therapeutic areas.
Quantifiable outcome
- Teplizumab (anti-CD3) approved by FDA as first disease-modifying therapy for Stage 3 T1D
- +2 more outcomes
Companies that use Immune Tolerance Network
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Immune Tolerance Network technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Immune Tolerance Network partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- JDRF (Juvenile Diabetes Research Foundation)coreITN partners with JDRF on type 1 diabetes research, including establishing a multi-center network for preclinical screening of combination therapies to accelerate translation to clinic
- Diabetes UKminorCollaborative partner for type 1 diabetes mechanistic assay development and standardization through TrialShare
- TrialNetminorCollaborative consortium partner for sharing T1D mechanistic assays and harmonizing data analysis across trials
- Northwestern UniversityminorClinical trial site for liver transplant tolerance study (EVR and EPO), led by Dr. Sandy Feng
- UCSF (University of California San Francisco)corePrimary research partner and office location; hosts Network Director Mark Anderson; multiple trial sites including liver transplant and T1D studies
- Benaroya Research InstitutecoreSeattle-based office location; hosts T1D trials including EXTEND tocilizumab study under Drs. Greenbaum and Buckner
- Yale School of MedicineminorClinical trial site for AbATE teplizumab study under Dr. Kevan Herold
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Immune Tolerance Network competitors and assessment
Company assessmentBroad incumbents
- Provention Bio (a Sanofi company): Sanofi acquired Provention Bio, the developer of teplizumab (Tzield)—the asset originated in ITN's AbATE trial. As the commercializer of ITN-validated therapies, Sanofi is the principal downstream industry partner benefiting from ITN's pipeline.
Direct peers
- AIDS Clinical Trials Group (ACTG): NIAID-sponsored clinical trials network running multicenter trials in HIV therapeutics. Operates under the same NIAID/NIH funding model as ITN and uses comparable multicenter academic medical center trial infrastructure with centralized specimen and data sharing.
- Children's Oncology Group (COG): NCI-funded pediatric cancer clinical trials consortium with a longstanding multicenter academic model, standardized protocols, and shared specimen/data assets. Operationally comparable to ITN's structure across four therapeutic disease areas.
- Cancer Immunotherapy Trials Network (CITN): CITN conducts early-phase immunotherapy clinical trials through a network of leading academic centers, sharing ITN's structure of mechanistic trial design, biomarker/immune monitoring, and partnership with NIH-funded institutions.
- Type 1 Diabetes TrialNet: NIH-funded clinical trial network focused on Type 1 Diabetes prevention and intervention. ITN's designated partner in T1D research and the closest structural sibling—same NIH sponsorship model, same multi-center academic trial design, overlapping principal investigators.
- NIAID Inner-City Asthma Consortium (ICAC): NIAID-funded clinical trial network conducting allergen and asthma intervention trials in pediatric populations. Directly comparable to ITN's allergy and asthma therapeutic area and shares the same NIAID sponsorship.
Emerging players
- MacroGenics: Clinical-stage biopharmaceutical company developing antibody-based therapeutics in immune tolerance and oncology. Pursues overlapping T cell and immune pathway targets, though as a commercial biotech rather than a research consortium.
- Abata Therapeutics: Biotech developing engineered regulatory T cell (Treg) therapies for autoimmune disease. Conceptually aligned with ITN's Treg-enhancement mechanistic trial designs and pursues overlapping indications in autoimmunity.
- Cartesian Therapeutics (formerly Selecta Biosciences): Clinical-stage biotech developing tolerogenic immunotherapies and cell therapy platforms designed to modulate immune response. Operates in the same immune tolerance therapeutic space as ITN-funded academic trials.
Others
- National Institute of Allergy and Infectious Diseases (NIAID): ITN's primary federal sponsor and an enabling organization that funds the network's clinical trial operations. Not a competing peer but the institution whose priorities directly shape ITN's research agenda and funding continuity.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Immune Tolerance Network social profiles
Digital presenceImmune Tolerance Network compliance and trust
Trust signalCompliance1 record
Immune Tolerance Network financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immune Tolerance Network leadership team
Management profileNumber of profiles
Profiles6 records
Immune Tolerance Network funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immune Tolerance Network M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immune Tolerance Network
What does Immune Tolerance Network do?
ITN is a research consortium that develops, funds, and conducts mechanistic clinical trials designed to re-establish immune tolerance in four therapeutic areas: allergy & asthma, autoimmune disease, transplantation, and type 1 diabetes. It operates TrialShare, a web-based data sharing platform providing researchers with access to raw clinical trial data, analysis tools, and banked clinical specimens from over 15 years of trials.
Is Immune Tolerance Network a public or private company?
Immune Tolerance Network is a private company. It is classified as state government owned and is currently operating.
When was Immune Tolerance Network founded?
Immune Tolerance Network was founded in -1. It employs 51 to 100 people.
Where is Immune Tolerance Network based?
Immune Tolerance Network is headquartered in Seattle, United States, in the North America region.
How does Immune Tolerance Network make money?
One revenue line is on record: government Research Funding.
Who are Immune Tolerance Network's main competitors?
Provention Bio (a Sanofi company) is listed as a broad incumbent. Direct peers are AIDS Clinical Trials Group (ACTG), Children's Oncology Group (COG), Cancer Immunotherapy Trials Network (CITN), Type 1 Diabetes TrialNet and NIAID Inner-City Asthma Consortium (ICAC). Emerging players are MacroGenics, Abata Therapeutics and Cartesian Therapeutics (formerly Selecta Biosciences). National Institute of Allergy and Infectious Diseases (NIAID) is listed as an others.
Does Immune Tolerance Network have an API?
No public API is recorded for Immune Tolerance Network.
What industry is Immune Tolerance Network in?
Immune Tolerance Network's product category is Clinical Research Services. Its primary akta.pro industry code is HLAAALAK, Autoimmune & Allergy Diagnostics. Its NAICS code is 5417 and its SIC code is 8731.